Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(33%)
Results Posted
100%(2 trials)

Phase Distribution

Ph early_phase_1
1
33%
Ph phase_4
1
33%
Ph phase_2
1
33%

Phase Distribution

1

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(2)

Detailed Status

Completed2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 41 (33.3%)

Trials by Status

recruiting133%
completed267%

Recent Activity

1 active trials
Showing 3 of 3
recruitingearly_phase_1

Immunomodulatory Therapy and Predictors of Clinical Cure in Chronic Hepatitis B

NCT07328711
completedphase_4

LT F-up Study 16-20 Yrs After Vaccine Dose of Hepatitis B With/Without HBIg in Newborns to HBeAg+ Mothers

NCT00240526
completedphase_2

Truvada Versus Truvada Plus Hepatitis B Immunoglobulin (HBIg) in Prevention of Chronic Hepatitis B Recurrence Post Liver Transplant

NCT00507689

Clinical Trials (3)

Showing 3 of 3 trials
NCT07328711Early Phase 1

Immunomodulatory Therapy and Predictors of Clinical Cure in Chronic Hepatitis B

Recruiting
NCT00240526Phase 4

LT F-up Study 16-20 Yrs After Vaccine Dose of Hepatitis B With/Without HBIg in Newborns to HBeAg+ Mothers

Completed
NCT00507689Phase 2

Truvada Versus Truvada Plus Hepatitis B Immunoglobulin (HBIg) in Prevention of Chronic Hepatitis B Recurrence Post Liver Transplant

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3